After a round a layoffs this summer, Lund, Sweden-based biotech BioInvent International has revealed further staff cutbacks as it hones in on cancer drug R&D. The biotech plans to let go of 20 jobs, adding to the 21 workers' positions axed this summer with the failure of a mid-stage study of its long-acting anticoagulant in partnership with ThromboGenics. Now CEO Svein Mathisen plans to keep 48 staffers on board, including 38 researchers, to focus on an oncology program that features a multiple myeloma drug candidate called BI-505 in Phase I development and two preclinical contenders. Article